Insider Transactions in Q4 2022 at Enanta Pharmaceuticals Inc (ENTA)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2022
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,500
+1.81%
|
$391,500
$27.58 P/Share
|
|
Dec 19
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,148
+4.62%
|
$58,072
$14.18 P/Share
|
|
Dec 16
2022
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.26%
|
$1,320,000
$44.54 P/Share
|
|
Dec 16
2022
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+1.85%
|
$420,000
$14.09 P/Share
|
|
Dec 01
2022
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-1.9%
|
$21,912
$44.33 P/Share
|
|
Dec 01
2022
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,659
-0.73%
|
$248,996
$44.33 P/Share
|
|
Dec 01
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,055
-1.28%
|
$46,420
$44.33 P/Share
|
|
Dec 01
2022
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,055
-0.29%
|
$46,420
$44.33 P/Share
|
|
Dec 01
2022
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,055
-1.76%
|
$46,420
$44.33 P/Share
|
|
Dec 01
2022
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-1.89%
|
$21,912
$44.33 P/Share
|
|
Nov 23
2022
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+25.89%
|
-
|
|
Nov 23
2022
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,500
+41.24%
|
-
|
|
Nov 23
2022
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,500
+41.37%
|
-
|
|
Nov 23
2022
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
63,000
+7.48%
|
-
|
|
Nov 23
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+20.28%
|
-
|
|
Nov 23
2022
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+5.51%
|
-
|
|
Nov 23
2022
|
Scott T. Rottinghaus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+20.59%
|
-
|